Affiliation:
1. Sinclair Dermatology
2. University of Melbourne , Melbourne , Australia
Abstract
In this response to a recent article on the off-label use of baricitinib for paediatric alopecia areata (AA), we raise additional points regarding the relationship between viral infections and AA relapse on Janus kinase inhibitor (JAKi) therapy, and the potential benefits of concomitant oral minoxidil therapy in mitigating the risk of relapse during JAKi dose reduction or discontinuation.
Publisher
Oxford University Press (OUP)
Reference9 articles.
1. Comment on ‘Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children’;Buontempo;Br J Dermatol,2023
2. Hair follicle immune privilege and its collapse in alopecia areata;Bertolini;Exp Dermatol,2020
3. Evidence that the bulge region is a site of relative immune privilege in human hair follicles;Meyer;Br J Dermatol,2008
4. Interferon-gamma is a potent inducer of catagen-like changes in cultured human anagen hair follicles;Ito;Br J Dermatol,2005
5. Cyclic dermal BMP signalling regulates stem cell activation during hair regeneration;Plikus;Nature,2008